Calendar

Arm has AI/cloud compute demand and a positive whisper above consensus, but checked calendar sources consistently place its report on November 4 rather than the supplied November 5 date; additionally, shares sold off sharply into the report alongside the semiconductor sector.

Shares rallied sharply on oncology optimism and recent sessions saw elevated volume, but checked pre-event estimates show a negative Earnings ESP and widening annual loss consensus; the latest three sessions also lacked a close-location reading above 0.75.

BAM had a strong Nov. 2 up-session on roughly twice the recent volume, with a close in the upper part of its range and a supportive financial-sector session. However, the checked estimate-revision source reports EPS consensus down 2.56% over 30 days, so the required positive EPS revision/ESP/whisper signal is absent; the setup does not qualify despite supportive price action and positive year-over-year estimates.

HUM has a confirmed November 6 report and strong prior-quarter execution, but current quarter consensus implies a substantial EPS decline and the stock has weakened over recent sessions; estimate-revision and revenue-upside evidence is inadequate, with no qualifying close-location or accumulation confirmation.

Vistra's date is company-confirmed and the Q3 consensus is available, but shares fell about 5% over the five sessions through Nov 2, closed near the session low, and no positive EPS/revenue revision or upside indicator was verified; the prior-quarter consensus EPS miss adds caution.

The business has a visible power-demand tailwind, but checked calendar sources describe Nov 9 as estimated rather than company-confirmed; estimates and recent price/volume evidence also do not establish the required positive tape setup.

KKR’s Nov. 2 rebound lifted the stock roughly 6.6% from Oct. 27, and the latest financial-sector session was positive; however, the Nov. 2 close was not in the top quarter of its daily range and volume was not convincingly above 1.5x normal. Zacks’ recent-estimate comparison was bearish despite a reported upward change in consensus EPS, and no positive revenue revision/upside signal was confirmed, leaving the required surprise setup incomplete.

A reported $3.36 whisper exceeds $3.28 consensus, and late-October price action was constructive, but no verified positive revenue revision/upside indicator or recent 1.5x volume signal was found; this does not clear the required setup bar.

OXY has a verified date and consensus EPS/revenue coverage, but no positive estimate-revision or revenue-upside evidence was found. Shares fell 5.13% on Nov. 2 on elevated volume and closed near the session low, while XLE dropped 3.96%; the required positive tape and sector-resilience signals are absent.

The shares rose over the latest five sessions and had one recent strong close, but no positive EPS revision or whisper gap was found, revenue estimates do not establish upside, and recent volume did not confirm accumulation. Prior company reporting described DTC and Studios growth offset by declining TV Media, leaving the setup incomplete.